Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.
CONCLUSIONS: Angiotensin-converting enzyme inhibition does not significantly modify major biomarkers of inflammation, hemostasis, and endothelial function. Further studies should confirm the possible effect of ACE inhibitors on the fibrinolysis pathway.
PMID: 19185642 [PubMed - in process] (Source: American Heart Journal)
Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects
Conclusion. The effective reduction of UAE with fosinopril was not related to plasma MMP-9 levels. (Source: Journal of the Renin-Angiotensin-Aldosterone System : JRAAS)
